SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing a parabolic surge, fueled by escalating industrial demand for silver in new technologies and anticipation of China's upcoming export restrictions. Community discussion highlights a potential short squeeze and belief that long-term price suppression is ending, though some anticipate a sharp correction after such an aggressive run.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending with gold prices reaching new all-time highs, driven by escalating geopolitical tensions, a weakening dollar, and widespread anticipation of significant Fed monetary easing. The community is actively debating whether this surge reflects a "currency reset" and a flight to real assets amid an over-indebted global environment, or if it signals an overheated market due for a correction, with many noting a rotation of investment capital from cryptocurrencies into precious metals.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending due to significant community discussion around its unique position as a Bitcoin-native memecoin, particularly on the Runes protocol. Bulls are highlighting recent strategic acquisitions by C2 Blockchain, which has notably expanded its $DOG treasury. The "DOG Army" expresses strong conviction, positioning $DOG as a contender to "drop the E" and become a dominant meme asset on the secure Bitcoin network.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is experiencing extreme price volatility and massive trading volume, sparking widespread community discussion around a potential short squeeze. Traders are actively debating its rapid movements, with some anticipating significant further momentum while others caution about the inherent risks of such speculative, low-float plays. The overall sentiment is sharply divided between those betting on continued upside and those warning of a pump-and-dump dynamic.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is experiencing significant attention as the community widely discusses a powerful silver squeeze, driven by a growing structural supply deficit and surging industrial demand across critical sectors. Many believe long-standing market suppression is breaking, potentially leading to a historic price discovery phase. Investor conversations emphasize the intrinsic value of physical silver as a hedge against broader economic uncertainties.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is currently trending amidst widespread community belief in a historic silver breakout, driven by strong industrial demand, geopolitical instability, and anticipation of central bank dovish pivots. Investors are actively discussing extreme upside targets for silver and its leveraged ETFs, with many highlighting its undervalued status relative to gold and expressing a "silver squeeze" narrative.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is generating significant community buzz, with enthusiasts proclaiming it "the chosen one" and positioning it as Grok's anticipated AI companion in the digital space. The conversation centers on its potential as the future of artificial intelligence within crypto, encouraging holders to "byte the dip" and maintain their positions for long-term prospects.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending due to its real-world asset integration via Cocky Wings LLC, which is actively generating revenue and performing token buybacks, enhancing liquidity. The community on Cardano is highly engaged, discussing its new DApp, passive earning opportunities in the 'Arena,' and its long-term potential as a utility-backed meme coin.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the landmark FDA approval of YARTEMLEA, establishing it as the first and only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in both adult and pediatric patients. This pivotal de-risking event, coupled with its strengthened financial position from a major partnership, has fueled community excitement regarding commercialization potential, anticipated analyst upgrades, and significant upside ahead of its upcoming conference call.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending amid significant trading volume, driven by renewed investor interest in its compute-in-memory (CIM) APU technology following sector developments. The community is actively debating the company's potential as a disruptive force in edge AI, with discussions centering on its low-power Gemini chips for defense, drone, and satellite applications, including partnerships. Anticipation for upcoming multi-modal large language model benchmarks is also fueling conversation around GSIT's unique position in the evolving AI hardware landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company...

Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research report on Thursday...

Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Plus Therapeutics in a research report on Monday...

HC Wainwright Expects Weaker Earnings for Plus Therapeutics

Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Research analysts at HC Wainwright reduced their FY2027 EPS estimates for shares of Plus Therapeutics in a report issued on Wednesday, November...

What is HC Wainwright's Estimate for PSTV Q1 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Plus Therapeutics in a research note...

Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $19.00

Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday...

&nbsp;November 20, 2025<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.plustherapeutics.com/node/17491/pdf">PDF Version</a>HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-LjgaMRZ499BxpnVFdK1_OIruUYH174LnCXs-fy9J1I_eFQqC3JpTBwOvH766dIT1nH5xLfntIINbP5tEdkB0SDLQG78HFGAOU5BkEJHktWlDyLHpCuy4sMdy9V6Ic4WNMutQlg4-mtVdYtWYaiL2IGkfMeZRCJwGfExniMB_2c8rF2BDTDExok63zegxo0Zzz8pCRIM_zGVoZ1pjMraVCsb47ACHDjHfm535tp8HDAGNMMlGzQxU4v50bSczESWKo6x314ti5HzsTYfN5TjFKj_R0Svs0TsL0Fpuw4o_V2QfDL515ej-QxrOcQDGzj83Xv55B3FzhnQtPM8CwzhHpEEtGvzFWKaNufvlmTXXGcjoyYpySS0ASePbFZjDn0SFCVDnbn2ujI2mvrDFn_YPj4uRtUZKd_u84vRPxhML9hM-8bd2N6am39WyHccsrghDSIS-9PtjI-w5QT1fbwrMTOplD0Zgp5-7lDPMm_u6rKd-HDKnSTsf1VW9kP-ssxp">Plus Therapeutics, Inc.</a>&nbsp;(Nasdaq:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Qc6X8S3RzScKVxvNu5_ceEM5GEv1Pptj0kvVK2trVYTrKl52rKHptUJcMeFv_r8m6XJ1xYecZnTL9qsMJK-c4D7wONMnr4cOMHuhbyC-B_5ohVVGYSzEJF3Bkl7p1l7wVA64zTIak8hwab7N7Mq556tOQzJlP6kOnE85RNx-iO3w5Wba49-0HAevN_Q0AzurlwzNjWv5cenpZgxc6bFvdrGmTjJRaW_JSEuTLAnXmNlti0LfISAeX284Eg18Lpu6kaosboSHHlT-jVrzzC9bF_XHIR2lKjlwRHyA34hiRVgqvNNrk9BKENa4lSbOz0hxdMgude4ZKO_7LMkYeJ78D5qOqeh8jDUAgckGvzK6XSj4sPM3rAs4MMrV6u79J2HmkaRunbqmC4i9TaFzG2JElk80i-xPqB7Ud8a_0MZs9BXT5C7FRTNYAtbyUh38Wl1-">PSTV</a>) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Ckx5KRl7GkjOTsknevCsv0V8yLayXt9wPOfKjhKbZbbUPUtJYQQ1s_3WMPrcWwJKkvtnm3wVcl2NqQk3TgY1p2feIGsp1Q-lDBhIyjds9Qo=">HUM</a>), effective&nbsp;October 29, 2025, covering approximately 16 million people throughout&nbsp;the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.About CNSide Diagnostics, LLC&nbsp; CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z85jinISrbvcaCeYclceVpAt9mO3Wi78ljN4HTR9BVI1smJG5x77F_beqPHrp5vSTUx_fkwpPQaECwHXeOdYGN4=">https://www.cnside-dx.com/</a>.About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z35nW-kNODbXQZtlDECdtGDGWCcawXezTzcic5Wa0-GT7YTxFESUvgVo1SXipvsyvJqzICHTRIfUoONu9xOH9uwwt2yHEFxsHOOelgYY9iSs">https://www.plustherapeutics.com</a>.About HumanaHumana Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=sVqa190sv-OGip6yFjYGO0t_cm6VKwY3aysRDxYxSjt0DTCbL2OqMK2Oz0V0BVN0kxVxe1yu5iCIPHAl4xJijJT_ANoSx8Di9opJClAXJ3U=">HUM</a>) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.Investor Contact CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investor@plustherapeutics.com">investor@plustherapeutics.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics, a Plus Therapeutics subsidiary, secured a national agreement with Humana to provide its CNSide CSF Tumor Cell Enumeration test, expanding coverage to 67 million people.

Others

Plus Therapeutics (NASDAQ:PSTV) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $5.00 target price on shares of Plus Therapeutics in a research note on Thursday...

Plus Therapeutics (NASDAQ:PSTV) Downgraded to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday...

Plus Therapeutics (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims Buys 20,000 Shares

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims acquired 20,000 shares of the firm's stock in a transaction on Tuesday, November 4th. The shares were bought...

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTV News

PSTVPlus Therapeutics Inc